Head-To-Head Survey: Avenue Therapeutics (NASDAQ:ATXI) and Endonovo Therapeutics (OTCMKTS:ENDVD)

Profitability

This table compares Avenue Therapeutics and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Valuation & Earnings

This table compares Avenue Therapeutics and Endonovo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38 million	$0.76	0.20
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A

Endonovo Therapeutics has higher revenue and earnings than Avenue Therapeutics. Endonovo Therapeutics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Avenue Therapeutics has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Institutional and Insider Ownership

17.3% of Avenue Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.